Citius Pharmaceuticals, Inc.
-$31.34M- Market cap
- $16.49M
- Debt
- +-$6.11M
- Cash
- −$41.71M
Capital structure 159% equity / -59% debt · EV / EBITDA 0.95x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CTXR stock price vs SMCI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SMCI's multiple
Needs SMCI P/S.
Implied fair value · at CTXR's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CTXR FY 2022 (ended Sep 30, 2022) · SMCI FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 159% equity / -59% debt · EV / EBITDA 0.95x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Super Micro Computer, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.06x
0.84x
Net debt / EBITDA
Leverage against operating earnings
1.45x
1.56x
Cash and equivalents
Liquid reserves on the balance sheet
$41.71M
$7.54B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zomedica Corp.
CTXR vs ZOM
Aquestive Therapeutics, Inc.
CTXR vs AQST
ACADIA PHARMACEUTICALS INC
CTXR vs ACAD
AMGEN INC
CTXR vs AMGN
GILEAD SCIENCES, INC.
CTXR vs GILD
AbbVie Inc.
CTXR vs ABBV
NVIDIA CORP
CTXR vs NVDA
INTEL CORP
CTXR vs INTC
CISCO SYSTEMS, INC.
CTXR vs CSCO
ADVANCED MICRO DEVICES INC
CTXR vs AMD
-$6.11M
$12.11B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.